Clear Street upgraded Korro Bio (KRRO) to Buy from Hold with a price target of $18, up from $10. The firm believes new lead program, KRRO-121 for hyperammonemia, clearly addresses an unmet need in the space and that the scientific rationale behind the approach is “strong,” the analyst tells investors. While acknowledging that significant clinical de-risking remains, it believes the risk/reward proposition “skews strongly in favor” of Korro at current trading levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio upgraded to Outperform from Market Perform at William Blair
- Korro Bio management to meet virtually with Cantor Fitzgerald
- First Solar downgraded, Fortinet upgraded: Wall Street’s top analyst calls
- Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
- Korro Bio upgraded to Buy from Neutral at Chardan